Monday, January 27, 2025

Investigating the effect of alemtuzumab in allogeneic hematopoietic cell transplantation

The OS and GEFS of the study cohort. The solid line and the dashed line show OS and GEFS curves, respectively. OS and GEFS at 2 years post-HCT are described with 95% confidence intervals in brackets. Grade III–IV acute GVHD, systemically treated chronic GVHD, second transplantation, and death were defined as failure events for GEFS. OS, overall survival; GEFS, graft-versus-host disease-free, event-free survival. Credit: Department of Child Health and Development, TMDU Allogeneic hematopoietic cell transplantation (HCT) is a commonly used curative therapy for individuals with inborn errors of immunity (IEI). HCT involves introducing stem cells from a compatible donor with Read More

No comments:

Post a Comment